Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma
Andrea Matucci, Enrico Maggi, Alessandra Vultaggio
Respiratory Medicine (2019) Vol. 160, pp. 105819-105819
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Eosinophils in the tumor microenvironment: implications for cancer immunotherapy
Sasan Ghaffari, Nima Rezaei
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 51
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme
David J. Jackson, Girolamo Pelaia, Benjamin Emmanuel, et al.
European Respiratory Journal (2024) Vol. 64, Iss. 1, pp. 2301521-2301521
Open Access | Times Cited: 19
Type 2 inflammation and biological therapies in asthma: Targeted medicine taking flight
Imran Howell, Aleksandra Howell, Ian Pavord
The Journal of Experimental Medicine (2023) Vol. 220, Iss. 7
Open Access | Times Cited: 26
TMT-based quantitative proteomics reveals suppression of SLC3A2 and ATP1A3 expression contributes to the inhibitory role of acupuncture on airway inflammation in an OVA-induced mouse asthma model
Weifeng Tang, Ming Dong, Fangzhou Teng, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 134, pp. 111001-111001
Open Access | Times Cited: 65
Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity
Rania Dagher, Varsha Kumar, Alan M. Copenhaver, et al.
European Respiratory Journal (2021) Vol. 59, Iss. 3, pp. 2004306-2004306
Open Access | Times Cited: 42
ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study
Francesco Menzella, Elena Bargagli, Maria Aliani, et al.
Respiratory Research (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 28
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
Alessandra Vultaggio, Maria Aliani, Elena Altieri, et al.
Respiratory Research (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 20
<p>Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma</p>
Nora Drick, Katrin Milger, Benjamin Seeliger, et al.
Journal of Asthma and Allergy (2020) Vol. Volume 13, pp. 605-614
Open Access | Times Cited: 39
Allergic Aspects of IgG4-Related Disease: Implications for Pathogenesis and Therapy
Despina Michailidou, Daniella M. Schwartz, Tomas Mustelin, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 34
Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: recent developments and future perspectives
Jacek Plichta, Piotr Kuna, Michał Panek
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 14
Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma
Corrado Pelaia, Maria Teresa Busceti, Claudia Crimi, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 129, pp. 110444-110444
Open Access | Times Cited: 34
Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells
Sisi Chen, Gaoying Chen, Fang Xu, et al.
Cell Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 20
Severe Asthma and Active SARS-CoV-2 Infection: Insights into Biologics
Sara Manti, Michela Leotta, F. D’Amico, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 674-674
Open Access
A real-life evaluation of SNOT-22 domains in a cohort of CRSwNP patients treated with biologic therapies for 12 months
Giulia Costanzo, Andrea Ledda, Giada Sambugaro, et al.
World Allergy Organization Journal (2025) Vol. 18, Iss. 3, pp. 101041-101041
Open Access
Tartaric Acid Exacerbates DSS-Induced Colitis by Promoting Eosinophilic Inflammation via IL-13 and IL-5Rα Upregulation
Bushra Riaz, Hye-Myung Ryu, Bunsoon Choi, et al.
Pathogens (2025) Vol. 14, Iss. 4, pp. 366-366
Open Access
Allergic Asthma-Induced Cognitive Impairment is Alleviated by Dexamethasone
Mengli Ren, Min Feng, Zhimin Long, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 26
Therapeutic effects of Pulsatilla koreana Nakai extract on ovalbumin-induced allergic rhinitis by inhibition of Th2 cell activation and differentiation via the IL-4/STAT6/GATA3 pathway
Dong Ho Jung, Ami Lee, Youn–Hwan Hwang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114730-114730
Open Access | Times Cited: 10
Comprehensive evaluation of type 2 endotype and clinical features in patients with chronic rhinosinusitis with nasal polyps in Taiwan: a cross-sectional study
Yi‐Tsen Lin, Chih‐Feng Lin, Chun‐Kang Liao, et al.
European Archives of Oto-Rhino-Laryngology (2023) Vol. 280, Iss. 12, pp. 5379-5389
Closed Access | Times Cited: 9
Eosinophilic Patterns in Patients with Seasonal Allergy Affected by Bronchial Asthma and Rhinitis/Rhinosinusitis: Efficacy of Benralizumab in Patients with the Persistent Pattern
Valentina D’Aiuto, Ilaria Mormile, Francescopaolo Granata, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 3, pp. 754-754
Open Access | Times Cited: 3
Angelica gigas extract ameliorates allergic rhinitis in an ovalbumin-induced mouse model by inhibiting Th2 cell activation
Kon-Young Ji, Dong Ho Jung, Bo‐Jeong Pyun, et al.
Phytomedicine (2021) Vol. 93, pp. 153789-153789
Open Access | Times Cited: 23
Targeting eosinophils in respiratory diseases: Biological axis, emerging therapeutics and treatment modalities
Li-Yen Lee, Geena Suet Yin Hew, Meenu Mehta, et al.
Life Sciences (2021) Vol. 267, pp. 118973-118973
Open Access | Times Cited: 21
Efficacy of mepolizumab in elderly patients with severe asthma and overlapping COPD in real-world settings: A retrospective observational study
Shoko Isoyama, Nobuhisa Ishikawa, Kosuke Hamai, et al.
Respiratory Investigation (2021) Vol. 59, Iss. 4, pp. 478-486
Closed Access | Times Cited: 21
Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy
Agamemnon Bakakos, Νikoletta Ρovina, Petros Bakakos
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 8, pp. 3969-3969
Open Access | Times Cited: 21
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting
Paolo Cameli, Laura Bergantini, Miriana d’Alessandro, et al.
International Archives of Allergy and Immunology (2020) Vol. 181, Iss. 8, pp. 606-612
Closed Access | Times Cited: 21
Current and emerging biological therapies for Chronic rhinosinusitis with nasal polyps with type 2 inflammation
Zeyi Jin, Bing Yan, Luo Zhang, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 10, pp. 909-919
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top